Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm
Status:
Completed
Trial end date:
2021-06-04
Target enrollment:
Participant gender:
Summary
This arm is a positron emission tomography (PET) biomechanistic GABA-A receptor target
engagement study that includes detailed clinical and motor assessments before and after the
i.v. administration of 1 mg flumazenil or placebo in Parkinson disease subjects. Each subject
will receive 1mg flumazenil or placebo at two visits.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Michigan
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)